Colorectal Cancer, NSCLC, Breast and Ovarian Cancer Represent the Most Common Indications Targeted By Drugs in Development - The Cancer Market Outlook To 2011.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c44749) has announced the addition of The Cancer Market Outlook to 2011 to their offering. Innovation is the key driving force in the cancer market, creating strong opportunities for biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. and pharma companies to launch new products and benefit from high volume sales and a strong competitive position. 'The Cancer Market Outlook to 2011' provides detailed analysis on 9 indications in the cancer market, identifying growth brands, key drug classes and leading companies. The 6-year epidemiology and product sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. detailed in this report will enable you to evaluate the changes in the competitive positions of leading companies in the cancer market and ensure your R&D pipeline is aligned with future market opportunity to sustain revenue growth. Use this report to benchmark the strategies behind the market-leading products of today and identify which products will be best positioned for growth over the period 2006-2011. Key findings of the report... -- New launches such as Erbitux, Avastin and Tarceva are set to continue to drive the rapid growth of the innovative market due to their utility across multiple indications, and superior efficacy profiles. -- Colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. , NSCLC NSCLC non (or cancer). NSCLC Non-small cell lung cancer, see there , breast and ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast represent the most common indications targeted by drugs in development, with an increasing focus also around indications such as renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. and NHL NHL Non-Hodgkin's lymphoma, see there , which while offering a small patient base pose significant incentives if molecules are granted orphan drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the status. -- The cytostatic cytostatic /cy·to·stat·ic/ (sit?ah-stat´ik) 1. suppressing the growth and multiplication of cells. 2. an agent that so acts. cy·to·stat·ic adj. 1. hormonals market, which has benefited from strong growth over the previous five years, no longer appears to be the growth driver it once was, as generic competition and a lack of innovation reduces prospects for growth. -- Product and development failure, low investment in emerging technologies and various R&D pipeline constructs are forecast to catalyze cat·a·lyze v. To modify, especially to increase, the rate of a chemical reaction by catalysis. catalyze to cause or produce catalysis. a shift in the top players over the forecast period. While Roche is forecast to extend its leading position within the cancer market through strong sales of MabThera, Avastin, Herceptin, Pegasys and Tarceva, increasing genericization is expected to cannibalize can·ni·bal·ize v. can·ni·bal·ized, can·ni·bal·iz·ing, can·ni·bal·iz·es v.tr. 1. To remove serviceable parts from (damaged airplanes, for example) for use in the repair of other equipment of the same AstraZeneca's cancer franchise. Key questions answered in this report -- What will be the major growth indications in the cancer market over the period 2006-11? -- Which companies were the winners and losers in the cancer market in 2005? -- How have recent major launches from BMS BMS abbr. Bachelor of Marine Science , Roche, Pfizer and Bayer/Onyx performed? -- Which companies will become the key players in the cancer market over the period 2006-11? -- Which products will be impacted by generic competitors over the period 2006-11? -- Which pipeline products will be the growth drivers of the future and why? -- Which indications are forecast to have the highest levels of market potential over the period 2006-11? Top five reasons to order your copy today -- Access the latest in research with the report's coverage of the 9 largest indications in the cancer market, the 7 largest geographic pharmaceutical markets and the 8 largest companies active in the cancer market today. -- Discover which indications have the greatest potential to provide franchise growth and how the pharmaceutical industry is attempting to utilize these opportunities. -- Evaluate how market share of leading companies, such as Roche, Novartis, Sanofi-Aventis and AstraZeneca will change over the next 6 years, and assess your competitive position within the market. -- Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the cancer marketplace. -- Gain access to the cancer pipelines of the 8 leading players to understand which companies will have a presence in key indications over the next 6 years. Content Outline: Executive Summary Patient potential Global market analysis Analysis of potential future cancer blockbusters Leading players in the cancer market Chapter 1 Patient potential Chapter 2 Global market analysis Chapter 3 Analysis of potential future Chapter 4 Leading players in the cancer market Chapter 5 Appendix Glossary Index List of Figures List of Tables Companies Mentioned: -- Roche -- Sanofi-Aventis -- Amgen -- AstraZeneca -- Novartis -- Johnson & Johnson -- Schering-Plough -- Lilly For more information visit http://www.researchandmarkets.com/reports/c44749 Source: Business Insights |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion